Tilmicosin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03977 |
| CAS | 108050-54-0 |
| Molecular Weight | 869.13 |
| Molecular Formula | C46H80N2O13 |
| Purity | >98% |
Ordering Information
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-03977 | 25 g | $197 | In stock |
Online Inquiry
Add to cartDescription
Tilmicosin is a macrolide antibiotic. Tilmicosin inhibits growth of Pasteurella multocida, Pasteurella haemolytica, Mycoplasma hyopneumoniae and certain other bacteria at levels of 6.25 μg/mL or less. It can prevent and treat bovine respiratory diseases caused by Pasteurella hemolyticus and Pasteurella multocida.
Specification
| Related CAS | 137330-13-3 (Phosphate) |
| Synonyms | EL 870; EL870; EL-870; Micotil 300 |
| Storage | Store at -20°C |
| IUPAC Name | (4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-7-[2-[(3R,5S)-3,5-dimethylpiperidin-1-yl]ethyl]-16-ethyl-4-hydroxy-15-[[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13-trimethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione |
| Canonical SMILES | CCC1C(C=C(C=CC(=O)C(CC(C(C(C(CC(=O)O1)O)C)OC2C(C(C(C(O2)C)O)N(C)C)O)CCN3CC(CC(C3)C)C)C)C)COC4C(C(C(C(O4)C)O)OC)OC |
| InChI | InChI=1S/C46H80N2O13/c1-13-36-33(24-57-46-44(56-12)43(55-11)40(53)31(8)59-46)19-25(2)14-15-34(49)28(5)20-32(16-17-48-22-26(3)18-27(4)23-48)42(29(6)35(50)21-37(51)60-36)61-45-41(54)38(47(9)10)39(52)30(7)58-45/h14-15,19,26-33,35-36,38-46,50,52-54H,13,16-18,20-24H2,1-12H3/b15-14+,25-19+/t26-,27+,28-,29+,30-,31-,32+,33-,35-,36-,38+,39-,40-,41-,42-,43-,44-,45?,46-/m1/s1 |
| InChI Key | JTSDBFGMPLKDCD-FXBZMSTBSA-N |
| Source | Semi-synthetic |
Properties
| Appearance | White Solid |
| Boiling Point | 926.6°C at 760 mmHg |
| Flash Point | 514.2ºC |
| Density | 1.18 g/cm3 |
| Solubility | Soluble in ethanol (25 mg/ml), methanol, DMF (25 mg/ml), DMSO (30 mg/ml) |
| LogP | 3.27930 |
Reference Reading
1.Whole Genome Sequence Analysis of Pig Respiratory Bacterial Pathogens with Elevated Minimum Inhibitory Concentrations for Macrolides.
Dayao DA1, Seddon JM1, Gibson JS1, Blackall PJ2, Turni C2. Microb Drug Resist. 2016 Mar 16. [Epub ahead of print]
Macrolides are often used to treat and control bacterial pathogens causing respiratory disease in pigs. This study analyzed the whole genome sequences of one clinical isolate of Actinobacillus pleuropneumoniae, Haemophilus parasuis, Pasteurella multocida, and Bordetella bronchiseptica, all isolated from Australian pigs to identify the mechanism underlying the elevated minimum inhibitory concentrations (MICs) for erythromycin, tilmicosin, or tulathromycin. The H. parasuis assembled genome had a nucleotide transition at position 2059 (A to G) in the six copies of the 23S rRNA gene. This mutation has previously been associated with macrolide resistance but this is the first reported mechanism associated with elevated macrolide MICs in H. parasuis. There was no known macrolide resistance mechanism identified in the other three bacterial genomes. However, strA and sul2, aminoglycoside and sulfonamide resistance genes, respectively, were detected in one contiguous sequence (contig 1) of A.
2.The Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuis.
Zhang P1, Hao H2, Li J1, Ahmad I1, Cheng G2, Chen D2, Tao Y2, Huang L2, Wang Y2, Dai M2, Liu Z3, Yuan Z4. Front Microbiol. 2016 Mar 22;7:385. doi: 10.3389/fmicb.2016.00385. eCollection 2016.
The aim of this study was to establish antimicrobial susceptibility breakpoints for tilmicosin against Haemophilus parasuis, which is an important pathogen of respiratory tract infections. The minimum inhibitory concentrations (MICs) of 103 H. parasuis isolates were determined by the agar dilution method. The wild type (WT) distribution and epidemiologic cutoff value (ECV) were evaluated by statistical analysis. The new bronchoaveolar lavage was used to establish intrapulmonary pharmacokinetic (PK) model in swine. The pharmacokinetic (PK) parameters of tilmicosin, both in pulmonary epithelial lining fluid (PELF) and in plasma, were determined using high performance liquid chromatography method and WinNonlin software. The pharmacodynamic cutoff (COPD) was calculated using Monte Carlo simulation. Our results showed that 100% of WT isolates were covered when the ECV was set at 16 μg/mL. The tilmicosin had concentration-dependent activity against H.
3.Antimicrobial susceptibility of Bordetella Avium and Ornithobacterium Rhinotracheale strains from wild and domesticated birds in Hungary.
Szabó R1, Wehmann E1, Magyar T1. Acta Vet Hung. 2015 Dec;63(4):413-24. doi: 10.1556/004.2015.039.
The antimicrobial susceptibility of 19 Bordetella avium and 36 Ornithobacterium rhinotracheale strains was tested by the Kirby-Bauer disk diffusion method, and the minimal inhibitory concentrations (MIC) of amoxicillin, doxycycline and erythromycin were also determined. Most O. rhinotracheale strains were resistant to nalidixic acid, sulphamethoxazole-trimethoprim and gentamicin, and were susceptible to ampicillin, chloramphenicol, spectinomycin and tilmicosin. All B. avium strains were resistant to ceftiofur and lincomycin and susceptible to doxycycline, gentamicin, polymyxin B, spectinomycin and sulphonamides. The MICs ranged widely for all three antibiotics tested against O. rhinotracheale strains, from 0.12 μg/ml to 32 μg/ml for amoxicillin and erythromycin, and from 0.6 μg/ml to 32 μg/ml for doxycycline. For B. avium isolates, the MIC values ranged from ≤ 0.03 μg/ml to 1 μg/ml for amoxicillin, from ≤ 0.03 μg/ml to 0.12 μg/ml for doxycycline and from 8 μg/ml to 16 μg/ml for erythromycin.
4.Separation analysis of macrolide antibiotics with good performance on a positively charged C18HCE column.
Wei J1, Shen A2, Yan J2, Jin G2, Yang B1, Guo Z2, Zhang F1, Liang X1,2. J Sep Sci. 2016 Mar;39(6):1073-81. doi: 10.1002/jssc.201500923. Epub 2016 Feb 24.
The separation of basic macrolide antibiotics suffers from peak tailing and poor efficiency on traditional silica-based reversed-phase liquid chromatography columns. In this work, a C18HCE column with positively charged surface was applied to the separation of macrolides. Compared with an Acquity BEH C18 column, the C18HCE column exhibited superior performance in the aspect of peak shape and separation efficiency. The screening of mobile phase additives including formic acid, acetic acid and ammonium formate indicated that formic acid was preferable for providing symmetrical peak shapes. Moreover, the influence of formic acid content was investigated. Analysis speed and mass spectrometry compatibility were also taken into account when optimizing the separation conditions for liquid chromatography coupled with tandem mass spectrometry. The developed method was successfully utilized for the determination of macrolide residues in a honey sample.
Recommended Products
| BBF-02614 | Nystatin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
